Unichem Laboratories gets USFDA approval for its Nebivolol Tablets

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval for its Nebivolol Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg from the United States Food and Drug Administration (USFDA)

Published On 2022-03-19 08:52 GMT   |   Update On 2023-10-10 12:09 GMT
Advertisement

Mumbai: Unichem Laboratories Limitedis pleased to announce that it has received ANDA approval for its Nebivolol Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Bystolic (nebivolol) Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg, of Allergan Sales, LLC. Nebivolol Tablets are indicated for the treatment of hypertension. The product will be commercialized from Unichem's Ghaziabad Plant.

Advertisement

Read Also - Unichem Labs gets USFDA nod for Divalproex Sodium ER Tablets

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. In India, The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms.

Read Also - Unichem Labs gets USFDA nod for Amitriptyline HCl Tablets

Unichem Laboratories was founded in 1944 by Late Mr. Amrut Mody, a pioneer in the Indian pharmaceuticals business. With a rich tradition of unwavering quality and reliability, Unichem brings together a unique blend of modern, value-added research and deep knowledge of the Indian pharmaceuticals industry.

Read Also - Unichem Labs gets USFDA nod for Metformin Hydrochloride ER Tablets







Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News